Global Cord Blood Corporation (CO)’s Financial Results Comparing With Cytori Therapeutics Inc. (NASDAQ:CYTX)

As Biotechnology businesses, Global Cord Blood Corporation (NYSE:CO) and Cytori Therapeutics Inc. (NASDAQ:CYTX), are affected by contrast. This especially applies to their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Global Cord Blood Corporation N/A 0.00 N/A 0.28 26.39
Cytori Therapeutics Inc. 6.65M 0.85 15.12M -3.90 0.00

Demonstrates Global Cord Blood Corporation and Cytori Therapeutics Inc. earnings per share, gross revenue and valuation.


Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Global Cord Blood Corporation 0.00% 7.2% 3.8%
Cytori Therapeutics Inc. -227.37% -261.3% -79.5%

Risk and Volatility

Global Cord Blood Corporation’s current beta is 0.41 and it happens to be 59.00% less volatile than Standard & Poor’s 500. Cytori Therapeutics Inc. on the other hand, has 2.03 beta which makes it 103.00% more volatile compared to Standard & Poor’s 500.


The Current Ratio of Global Cord Blood Corporation is 9.7 while its Quick Ratio stands at 9.6. The Current Ratio of rival Cytori Therapeutics Inc. is 0.6 and its Quick Ratio is has 0.4. Global Cord Blood Corporation is better equipped to clear short and long-term obligations than Cytori Therapeutics Inc.


$0.08 per share with a dividend yield of 1.16% is the annual dividend that Global Cord Blood Corporation pay. Cytori Therapeutics Inc. does not pay a dividend.

Institutional and Insider Ownership

Institutional investors held 17.4% of Global Cord Blood Corporation shares and 6.8% of Cytori Therapeutics Inc. shares. Global Cord Blood Corporation’s share held by insiders are 49.6%. Competitively, Cytori Therapeutics Inc. has 2.42% of it’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Global Cord Blood Corporation 3.79% 17.68% 15.29% 6.79% -29.82% 14.57%
Cytori Therapeutics Inc. -8.29% -28.42% -26.18% -57.89% -92.62% -17.24%

For the past year Global Cord Blood Corporation had bullish trend while Cytori Therapeutics Inc. had bearish trend.


Global Cord Blood Corporation beats Cytori Therapeutics Inc. on 9 of the 11 factors.

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2018, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).

Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments. The company also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and KaposiÂ’s Sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer. It serves hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through direct sales force, third-party distributors, independent sales representatives, and partners worldwide. The company was founded in 1996 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.